GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

A novel signaling mechanism for LRP5

$519,210
Dianqing Wu · Yale University · R01 · FY2024 · CA

Systemic RNA Delivery to Tumors

$518,820
Jinjun Shi · Brigham And Women'S Hospital · R01 · FY2024 · CA

Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity

$518,698
Kimmie Ng · Dana-Farber Cancer Inst · R01 · FY2022 · CA

Microbiota-Immune Interactions in CTLA-4 Antibody Blockade-Induced Colitis

$518,680
Gabriel Nunez · University Of Michigan At Ann Arbor · R01 · FY2025 · DK

Pro-tumorigenic functions of human DNA polymerases eta and kappa during genome duplication under physiological replication stress conditions

$518,614
Kristin A Eckert · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2019 · CA

Deciphering the Molecular Mechanisms Underlying Cholangiocarcinoma Development

$518,219
Sungjin Ko · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA

A New Immune Checkpoint Pathway in Human Bladder Cancer

$518,205
Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2024 · CA

Myct1 control of the angioimmune interface

$518,199
Kyunghee Choi · Washington University · R01 · FY2024 · CA

Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy

$518,180
Yong Wan · Emory University · R01 · FY2022 · CA

Project 2: Targeting differentiation-linked redox sensitivity in melanoma

$517,922
Thomas G Graeber · University Of California Los Angeles · P01 · FY2020 · CA

Project 2: Targeting differentiation-linked redox sensitivity in melanoma

$517,922
Thomas G Graeber · University Of California Los Angeles · P01 · FY2021 · CA

Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma

$517,920
Roger S Lo · University Of California Los Angeles · P01 · FY2021 · CA

Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma

$517,920
Roger S Lo · University Of California Los Angeles · P01 · FY2020 · CA

An integrated polymeric carrier for subunit cancer vaccines

$517,545
Suzie H Pun · University Of Washington · R01 · FY2025 · CA

(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition

$517,415
Justin M Balko · Vanderbilt University Medical Center · R01 · FY2021 · CA

Cooperation of Co-Amplified Genes in Hepatocellular Carcinoma

$517,389
Devanand Sarkar · Virginia Commonwealth University · P01 · FY2025 · CA

(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors

$517,329
Anton Wellstein · Georgetown University · R01 · FY2019 · CA

Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers

$517,263
Wenbin Lin · University Of Chicago · R01 · FY2020 · CA

Predictive experiment-based multiscale models of the tumor immune microenvironment and immunotherapy in breast cancer

$517,238
Aleksander S. Popel · Johns Hopkins University · R01 · FY2022 · CA

Project 1

$517,215
Ann G Schwartz · Wayne State University · P20 · FY2022 · CA

MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER

$516,975
Marco Ruella · University Of Pennsylvania · R37 · FY2023 · CA

Tissue Resident memory T cell responses to cancer

$516,944
Mary J Turk · Dartmouth College · R01 · FY2019 · CA

Translational Immunology

$516,832
Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Rare Central Nervous System Cancers Initiative

$516,832
Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.

$516,726
Gordon B. Mills · Oregon Health & Science University · U01 · FY2023 · CA